Showing 8491-8500 of 9657 results for "".
- Theradome Laser Helmet Launches for At-home Treatment of Hair Losshttps://practicaldermatology.com/news/20131219-theradome_laser_helmet_launches_for_at-home_treatment_of_hair_loss/2459389/Theradome Laser Helmet LH80 PRO, the first FDA and over-the-counter cleared, wearable laser hair restoration treatment, is now available. Developed for in-home use and designed for patients suffering from the effects of thinning hair and Androge
- AAD Issues New Guidelines for Diagnosis and Assessment of Atopic Dermatitishttps://practicaldermatology.com/news/20131204-aad_issues_new_guidelines_for_diagnosis_and_assessment_of_atopic_dermatitis/2459399/The American Academy of Dermatology (AAD) recently announced the release of its new evidence-based guidelines for the diagnosis and assessment of atopic dermatitis based on an extensive review of the scientific literature on this chronic skin condition characterized by itchy, re
- FDA Approves Varithena to Treat Varicose Veinshttps://practicaldermatology.com/news/20131127-fda_approved_varithena_to_treat_varicose_veins/2459401/The FDA recently approved BTG plc's Varithena (polidocanol injectable foam) for the treatment of patients with incompetent veins and visible varicosities of the great saphenous vein (GSV) system. V
- ASLMS Announces Dr. Horace Furumoto Award Recipientshttps://practicaldermatology.com/news/20131126-laser_society_announces_dr_horace_furumoto_award_recipients/2459402/Michael H. Slayton, Ph.D. and Ishan Barman, Ph.D. will receive the Horace Furumoto Innovations Professional Development Awards at the upcoming meeting of the American Society for Laser Medicine & Surgery, Inc. (ASLMS), which will be held in April 2014, in Phoenix, AZ. Dr. Thomas Rohrer, Chair of the
- Rigel Provides Pipeline Updatehttps://practicaldermatology.com/news/20131024-rigel_provides_pipeline_update/2459429/Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced updates on two of the Company's pipeline products: R333, a topical dermatological JAK/SYK inhibitor, and fostamatinib, an oral SYK inhibitor.
- Pfizer Announces Top-Line Results of Two Phase III Clinical Trials Of Tofacitinibhttps://practicaldermatology.com/news/20131021-pfizer_announces_top-line_results_of_two_phase_iii_clinical_trials_of_tofacitinib/2459433/Pfizer, Inc. recently announced top-line results from two Phase III clinical trials of tofacitinib, a novel, oral Janus kinase (JAK) inhibitor that is being investigated for the treatment of adults with moderate-to-severe chro
- ASDS Elects New Officers, Board Membershttps://practicaldermatology.com/news/20131016-asds_elects_new_officers_board_members/2459435/The American Society for Dermatologic Surgery (ASDS) announces the election of Naomi Lawrence, M.D., as Vice President as well as a new Secretary and three new board members during its Annual Meeting in Chicago. The Society's newly elected officials will join President Mitchel P. Goldman, M.D., and
- Hair Restoration Doctors Name Best Celebrity Hair, Meeting Convenes October 23https://practicaldermatology.com/news/20131010-hair_restoration_doctors_name_best_celebrity_hair_meeting_convenes_october_23/2459438/Singer/songwriter John Mayer and “Modern Family” star Sofia Vergara are the male and female celebrities with the most sought-after hair, according to results of the International Society of Hair Restoration Surgery (ISHRS) member survey released rec
- ALPHAEON Acquires Exclusive Worldwide Licensing Rights To TouchMDhttps://practicaldermatology.com/news/20131010-alphaeon_acquires_exclusive_worldwide_licensing_rights_to_touchmd/2459439/ALPHAEON Corp., a leader in lifestyle healthcare and wholly-owned subsidiary of Strathspey Crown Holdings LLC, announced today that it has acquired worldwide licensing rights to TouchMD, for an undisclosed amount. TouchMD is an interactive software platform that helps speciality physicians educate p
- Cimzia FDA Approved to Treat Active Psoriatic Arthritis in Adultshttps://practicaldermatology.com/news/20131001-cimzia_receives_fda_approval_to_treat_adults_with_active_psoriatic_arthritis/2459446/The FDA recently approved UCB's Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA). The FDA approval of Cimzia for active PsA is based on data from the RAPID-PsA study, an ongoing, Phase III, multicenter, randomized,